|  |  |  |
| --- | --- | --- |
| **CATEGORIES** | **KEY ELEMENTS AND ASSUMPTIONS** | **HYPOTHESIS** |
| Business/Market | No treatment for traumatic SCI patients | Paralyzed patients yearn to heal from this disabling condition |
| Technology | Production of a functioning autologous neural tissue | A functioning autologous neural tissue will bridge and regenerate injured Spinal Cord |
| Regulatory | Product will be fast tracked thru FDA | FDA will prioritize a breakthrough designation and orphan designation |
| Clinical | Clinical trials will be small | Following a breakthrough designation, the trial will be small (5-10 patients) |